Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344748 | 1.00 | PDE3B (0.43) | PDE3BPDE3ASLC9A1CYP3A4CYP2C19 | |
| SCHEMBL2340975 | 0.83 | SLC9A1 (0.45) | PDE3BPDE3ASLC9A1CYP3A4CYP2C19 | |
| SCHEMBL2340985 | 0.83 | SLC9A1 (0.45) | PDE3BPDE3ASLC9A1CYP3A4CYP2C19 | |
| SCHEMBL1962239 | 0.83 | NOTUM (0.50) | PDE3BPDE3ASLC9A1CYP3A4CYP2C19 | |
| SCHEMBL1962241 | 0.83 | NOTUM (0.50) | PDE3BPDE3ASLC9A1CYP3A4CYP2C19 | |
| SCHEMBL1972312 | 0.77 | PDE3B (0.43) | PDE3BPDE3ASLC9A1CYP3A4CYP2C19 | |
| SCHEMBL10156506 | 0.76 | MAPT (0.51) | PDE3BPDE3AGAAADRB2TP53 | |
| SCHEMBL1968214 | 0.70 | PDE3B (0.46) | PDE3BPDE3AADRB2 | |
| SCHEMBL1397423 | 0.70 | ALDH1A1 (0.55) | SLC9A1CYP3A4CYP2C19GAAMAPT | |
| SCHEMBL23865026 | 0.70 | MAPT (0.44) | NPC1GAARAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | PDE3B 214/4885PDE3A 220/4885SLC9A1 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.